All In Biotech

Drug Trial Radar · NCT06606093

Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center, Phase 3 Clinical Trial and Open-label Extension Clinical Trial to Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients (CKD Stage 3)

Last checked: Nov 19, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 348 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

348

Planned (sponsor's estimate)

Start

Sep 23, 2024

Primary completion

Sep 1, 2026

Study completion Jan 31, 2027

Sponsor

Sponsor type
Industry
First posted
Sep 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy and safety of DWP16001 in type 2 diabetic nephropathy with moderate renal impairment patients (CKD stage 3)

Conditions

  • Type 2 Diabetic Nephropathy

Interventions

  • DWP16001 PlaceboDrug

    1 tablet, Orally, Once daily single dose

  • DWP16001 0.3mgDrug

    1 tablet, Orally, Once daily single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c at Week 24 from Baseline after RandomizationTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Korea university ansan hospital

    Ansan, Gyeongggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.